Performing virtual reality simulations before TAVR may help cardiologists anticipate when PVL could be an issue in patients with severe BAV AS.

The program is a simplified modification of the popular Mirai deep-learning algorithm, developed by researchers at MIT to predict future cancer.

The company already received CE mark approval for its new PFA offering and hopes it will soon be approved for sale in the United States.

Cardior Pharmaceuticals in Germany has been developing a new compound it says can “halt and partially reverse cellular pathology” in heart failure patients. 

While the American College of Cardiology's annual meeting has historically had a more clinical focus, presentations at this year's conference in Atlanta will spend much more time looking at the business side of things. 

The news represents a meaningful policy shift for CMS. In the past, Medicare prescription drug plans have not covered medications designed to help patients lose weight.

New research explored the potential savings of turning off angiography systems at night and on weekends.

Eric Secemsky, MD, from Beth Israel Deaconess Medical Center and Harvard Medical School, says a lack of hands-on training and reimbursement challenges are hindering the adoption of IVUS.